Improvements in Lung Function and Height among Cohorts of 6-Year-Olds with Cystic Fibrosis from 1994 to 2012 - 21/11/14
Abstract |
Objective |
To characterize spirometry and height changes in cohorts of 6-year-old children with cystic fibrosis (CF).
Study design |
Global Lung Initiative forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC, and the Centers for Disease Control and Prevention height-for-age (HFA) z-scores were generated for 6-year-old children from the Cystic Fibrosis Foundation Patient Registry each year between 1994 and 2012. Z-score mean differences were analyzed by the t test, and time trends of means were analyzed by least squares regression for all children and for subgroups of sex, F508del mutation genotype, Medicaid insurance, and prenatal/newborn screening identification. Z-score distributions were compared using the 2-sample Kolmogorov-Smirnov test.
Results |
A total of 11 670 children with CF were studied, of whom 50.5% were males, 50.2% had the F508del/F508del genotype, and 46.6% were insured by Medicaid. Mean HFA, FEV1, and FVC z-scores increased significantly over the period in the entire cohort and in all subgroups (P < .001), but FEV1/FVC z-scores were below normal and did not change significantly. In 2012, children identified by screening had significantly higher mean HFA (P = .002), FEV1 (P < .001), and FVC (P < .001) z-scores compared with children not screened, with 90% of FVC and 71.4% of FEV1 z-scores greater than predicted by the normal distribution. FEV1/FVC z-scores were not different between the children who were and were not screened.
Conclusion |
Consistent, significant increases in HFA, FEV1, and FVC occurred between 1994 and 2012, but FEV1/FVC, a measure of airway obstruction, did not change appreciably during this period. FVC and FEV1 z-score distributions suggest that normative equation reference populations underpredict lung volumes of children with CF, but the reasons for this remain unclear.
Le texte complet de cet article est disponible en PDF.Keyword : CF, CFFPR, FEF25-75, FEV1, FEV1% predicted, FVC, GLI, HFA
Plan
M.K. was supported by the National Institutes of Health (P30 DK27651) and the Cystic Fibrosis Foundation (CFFT KONSTA09Y0), and has served as an advisor/investigator for Aradigm, Celtaxsys, Digestive Care Inc, Genentech, Gilead Sciences, Insmed, Novartis, Savara, and Vertex. D.vD. has served in the past year as an advisor/consultant for Affinium Pharmaceuticals, Aptalis Pharma, Aradigm, Baxter Healthcare, the US CF Foundation, CURx Pharma, Forest Pharmaceuticals, Genentech, Gilead Sciences, ICON Clinical Sciences, Kalobios, Vertex, and MedImmune. D.P. is employed by ICON Clinical Research, which provides clinical research services to pharmaceutical, biotechnology, and device companies. |
Vol 165 - N° 6
P. 1091 - décembre 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?